Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Merck & Co., Inc.    MRK

Delayed Quote. Delayed  - 07/22 10:00:15 pm
58.82 USD   +0.05%
07/22 MERCK : Data for Merck's Investigational Once-Daily Formulation of I..
07/21 MERCK ANIMAL HE : Receives FDA Approval of BRAVECTO® (fluralaner top..
07/21 MERCK : Provides Regulatory Update on Biologics Licensing Applicatio..
News SummaryMost relevantAll newsSector news 

Merck & Co., Inc. : Merck To Pay $321.6 Million Fine For Illegal Marketing Of Vioxx

share with twitter share with LinkedIn share with facebook
share via e-mail
04/19/2012 | 07:50pm CEST

A U.S. district court judge in Boston ordered Merck & Co. (MRK) to pay a $321.6 million criminal fine for its violation of a federal drug law in connection with its marketing of the former painkiller Vioxx.

In December, Merck pleaded guilty to violating the Federal Food, Drug, and Cosmetic Act for introducing a misbranded drug into interstate commerce. The company said it previously recorded a $950 million charge in October 2010 in anticipation of the settlement, which resolves a seven-year investigation.

Merck withdrew Vioxx from the market in 2004 after it was linked to a higher risk of heart attacks and strokes.

"The government recognized Merck's full cooperation with its investigation and by putting this long-standing investigation to rest, we can more fully focus on discovering, developing and providing innovative medicines and vaccines that save and improve lives around the world," Merck said in a statement.

In November, Merck had agreed to pay $950 million and plead guilty to a misdemeanor charge of marketing a misbranded drug, to resolve government allegations that the company illegally promoted Vioxx and deceived the government about the drug's safety. The government alleged that Merck promoted Vioxx for treatment of rheumatoid arthritis before that use was approved by regulators. A portion of the $950 million settlement also was to resolve parallel civil allegations that Merck made false and misleading statements about Vioxx's safety, causing government health programs to pay for the drug's use. Merck denied the civil allegations.

Shares were off 14 cents to $38.26 in recent trading. The stock is up 1.5% since the start of the year.

-By Nathalie Tadena, Dow Jones Newswires; 212-416-3287; nathalie.tadena@dowjones.com

share with twitter share with LinkedIn share with facebook
share via e-mail
Latest news on MERCK & CO., INC.
07/22 MERCK : Data for Merck's Investigational Once-Daily Formulation of ISENTRESS® (r..
07/21 MERCK ANIMAL HEALTH : Receives FDA Approval of BRAVECTO® (fluralaner topical sol..
07/21 MERCK : Provides Regulatory Update on Biologics Licensing Application for Invest..
07/21 MERCK : Patent Issued for Preparation of Crystalline Forms of Dihydropyrazolopyr..
07/21 MERCK : Findings in Pseudohypoparathyroidism and Genetics Reported from Merck & ..
07/21 MERCK : Findings on Enzymes and Coenzymes Reported by Researchers at Merck & Com..
07/20 U.S. healthcare stock bulls look past political risks
07/19 MERCK : A*STAR and MSD team up to advance peptide therapeutics
07/18DJMARKET SNAPSHOT : Dow On Track For Record Closing High As Tech Rallies
07/18DJGLAXOSMITHKLINE : China's Food and Drug Administration Approves GlaxoSmithKline'..
More news
Sector news : Pharmaceuticals - NEC
07/22DJJOHNSON & JOHNSON : Acclarent Unit in $18 Million U.S. Settlement
07/22DJJOHNSON & JOHNSON : Acclarent Unit in $18 Million U.S. Settlement
07/22DJBAYER : 2Q 2016 -- Forecast
07/22DJMonsanto Wins EU Nod for New Biotech Soybeans
07/21DJBIOGEN : Announces CEO Search, Lifts Guidance--2nd Update
More sector news : Pharmaceuticals - NEC
News from SeekingAlpha
07/22 OpGen - A Play Against Multiple Antibiotic Resistant Infection Many May Not H..
07/22 Healthcare ratings - upgrades/downgrades
07/21 FDA OKs Merck Animal Health's single-dose flea & tick treatment for dogs and ..
07/21 FDA requests new data on Merck's bezlotoxumab, action date pushed out to Octo..
07/21 BUY GILEAD : 4 Reasons Why
Financials ($)
Sales 2016 39 507 M
EBIT 2016 13 526 M
Net income 2016 6 432 M
Debt 2016 3 946 M
Yield 2016 3,14%
P/E ratio 2016 25,77
P/E ratio 2017 19,77
EV / Sales 2016 4,22x
EV / Sales 2017 4,21x
Capitalization 162 815 M
More Financials
Chart MERCK & CO., INC.
Duration : Period :
Merck & Co., Inc. Technical Analysis Chart | MRK | US58933Y1055 | 4-Traders
Full-screen chart
Technical analysis trends MERCK & CO., INC.
Short TermMid-TermLong Term
Technical analysis
Income Statement Evolution
More Financials
Mean consensus OUTPERFORM
Number of Analysts 22
Average target price 61,9 $
Spread / Average Target 5,2%
Consensus details
EPS Revisions
More Estimates Revisions
Kenneth C. Frazier Chairman, President & Chief Executive Officer
Robert M. Davis Chief Financial Officer & Executive Vice President
Michael A. Rosenblatt Chief Medical Officer & Executive Vice President
Clark Golestani Chief Information Officer & Executive VP
Thomas Henry Glocer Independent Director
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
MERCK & CO., INC.11.36%162 815
JOHNSON & JOHNSON21.72%343 913
PFIZER INC.13.82%222 823
NOVARTIS AG-5.13%219 526
ROCHE HOLDING LTD.-9.62%218 832
More Results